Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial-Reference-Cited by-同舟云学术

Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial

Published:2022-02-23 Issue:1 Volume:7 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Rollier Christine S.¹^ORCID,Dold Christina¹,Marsay Leanne¹,Linder Aline¹,Green Christopher A.¹,Sadarangani Manish¹^ORCID,Norheim Gunnstein²,Derrick Jeremy P.³,Feavers Ian M.⁴,Maiden Martin C. J.⁵^ORCID,Pollard Andrew J.¹

Affiliation:

1. Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

2. Norwegian Institute of Public Health, Oslo, Norway

3. School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom

4. National Institute for Biological Standards and Control, Hertfordshire, United Kingdom

5. Department of Zoology, University of Oxford, Oxford, United Kingdom

Abstract

Neisseria meningitidis outer membrane vesicles (OMV) are a component of the capsular group B meningococcal vaccine 4CMenB (Bexsero) and have been shown to induce 30% efficacy against gonococcal infection. They are composed of multiple antigens and are considered an interesting delivery platform for vaccines against several bacterial diseases.

Funder

NIHR | NIHR Oxford Biomedical Research Centre

Wellcome Trust

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/msphere.00674-21

Reference34 articles.

1. The changing and dynamic epidemiology of meningococcal disease

3. The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy